Welcome to chemicalbook!
400-158-6606
Try our best to find the right business for you.
Do not miss inquiry messages Please log in to view all inquiry messages.

Welcome back!

ChemicalBook > Product Catalogue >API >Digestive system drugs >Antacid and Mucosal protective Drugs >Rebamipide

Rebamipide

Rebamipide Structure
  • ₹5200 - ₹29541.43
  • Product name: Rebamipide
  • CAS: 90098-04-7
  • MF: C19H15ClN2O4
  • MW: 370.79
  • EINECS:1308068-626-2
  • MDL Number:MFCD00866895
  • Synonyms:(+-)-1,2-dihydro-alpha-((4-chlorobenzoyl)amino)-2-oxo-4-quinolinepropanoica ;(+-)-2-(4-chlorobenzoylamino)-3-(2(1h)-quinolinon-4-yl)propionicacid ;Mucosta;Proamipide;2-dihydro-alpha-((4-chlorobenzoyl)amino)-2-oxo- (+-)-4-quinolinepropanoic acid;2-(4-Chlorobenzoylamino)-3-(1,2-dihydro-2-oxo-4-quinolyl)propionic acid;2-(4-CHLOROBENZAMIDO)-3-(2-OXO-1,2-DIHYDROQUINOLIN-4-YL)PROPANOIC ACID;OPC-12759, Mucosta, α-[(4-Chlorobenzoyl)-amino]-1,2-dihydro-2-oxo-4-quinolinepropanoic Acid
5 prices
Selected condition:

Brand

  • TCI Chemicals (India)
  • Sigma-Aldrich(India)

Package

  • 5MG
  • 25MG
  • 1G
  • 5G
  • 25G
  • ManufacturerTCI Chemicals (India)
  • Product numberR0085
  • Product descriptionRebamipide
  • Packaging1G
  • Price₹5200
  • Updated2022-05-26
  • Buy
  • ManufacturerTCI Chemicals (India)
  • Product numberR0085
  • Product descriptionRebamipide
  • Packaging5G
  • Price₹5900
  • Updated2022-05-26
  • Buy
  • ManufacturerTCI Chemicals (India)
  • Product numberR0085
  • Product descriptionRebamipide
  • Packaging25G
  • Price₹20000
  • Updated2022-05-26
  • Buy
  • ManufacturerSigma-Aldrich(India)
  • Product numberR5655
  • Product descriptionRebamipide hydrate ≥98% (HPLC), powder
  • Packaging5MG
  • Price₹7404.3
  • Updated2022-06-14
  • Buy
  • ManufacturerSigma-Aldrich(India)
  • Product numberR5655
  • Product descriptionRebamipide hydrate ≥98% (HPLC), powder
  • Packaging25MG
  • Price₹29541.43
  • Updated2022-06-14
  • Buy
Manufacturer Product number Product description Packaging Price Updated Buy
TCI Chemicals (India) R0085 Rebamipide 1G ₹5200 2022-05-26 Buy
TCI Chemicals (India) R0085 Rebamipide 5G ₹5900 2022-05-26 Buy
TCI Chemicals (India) R0085 Rebamipide 25G ₹20000 2022-05-26 Buy
Sigma-Aldrich(India) R5655 Rebamipide hydrate ≥98% (HPLC), powder 5MG ₹7404.3 2022-06-14 Buy
Sigma-Aldrich(India) R5655 Rebamipide hydrate ≥98% (HPLC), powder 25MG ₹29541.43 2022-06-14 Buy

Properties

Melting point :288-290°C dec.
Boiling point :695.0±55.0 °C(Predicted)
Density :1.394±0.06 g/cm3(Predicted)
storage temp. :Sealed in dry,Room Temperature
solubility :DMSO: >5mg/mL
pka :3.38±0.10(Predicted)
form :powder
color :white
Merck :14,8124
InChIKey :ALLWOAVDORUJLA-UHFFFAOYSA-N
CAS DataBase Reference :90098-04-7(CAS DataBase Reference)

Safety Information

Symbol(GHS): GHS hazard pictograms
Signal word: Danger
Hazard statements:
Code Hazard statements Hazard class Category Signal word Pictogram P-Codes
H301 Toxic if swalloed Acute toxicity,oral Category 3 Danger GHS hazard pictograms P264, P270, P301+P310, P321, P330,P405, P501
Precautionary statements:
P301+P310 IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.

Description

Rebamipide is a quinolinone derivative that stimulates endogenous PGE2 generation in gastric mucosa, enhancing gastric mucosal defense in a COX-2-dependent manner.
Rebamipide has been shown to inhibit the production of reactive oxygen species and to decrease cytokine release induced by H. pylori infection.
A daily oral dose of 100 mg/kg was found to be protective against the development of pyloric channel ulcers in Mongolian gerbils infected with H. pylori.
In addition to the stomach, rebamipide can also enhance secretion of mucin covering the conjunctiva and cornea, which is important for tear film adhesion.
Rebamipide, a gastroprotective drug, was developed in Japan and was proven to be superior to cetraxate, the former most prescribed drug of the same category, in 1989 in the treatment for gastric ulcers. The initially discovered basic mechanisms of action of rebamipide included its action as a prostaglandin inducer and oxygen free-radical scavenger. In the last 5 years, several basic and clinical studies have been performed for functional dyspepsia, chronic gastritis, NSAID-induced gastrointestinal injuries, gastric ulcer following eradication therapy for Helicobacter pylori, gastric ulcer after endoscopic surgery and ulcerative colitis. In addition, several molecules have been identified as therapeutic targets of rebamipide to explain its pleiotropic pharmacological actions.

Related product price